Join Our Mailing List

Updates


Bill Maris and Kevin Rose Live on Clubhouse

Join us 3/4 on Clubhouse with Kevin Rose and Bill Maris!

Read More


Miroculus raises $45M in Extended Series B Financing

We are excited to partner with Miroculus to make state-of-the art healthcare available to patients in every setting.

Read More


Coinbase Files to go Public

“Coinbase Global Inc., the biggest U.S. cryptocurrency exchange, filed to go public via a direct listing”

Read More


Sema4 – CMLF

Sema4-CMLF merger makes its way to Times Square!

Read More


An update from Section 32

While 2020 was a year that no one wants to dwell on, we wanted to share a brief update about our progress and portfolio. We spent the past year thoughtfully building up our team and continuing to invest in areas that we believe can have an outsized positive impact on people’s lives, like early detection of cancer, more efficient and less expensive drug discovery, AI to improve patient experience, more secure cloud computing, and more.

Read More


sema4 announces SPAC

We are taking steps to become a public company by entering into an agreement with #SPAC CM Life Sciences (NASDAQ: CMLF). We expect this milestone to accelerate our mission to advance #healthcare via data-driven insights: hubs.la/H0GlJzk0

Read More


Metromile is listed on the Nasdaq

Metromile is #NasdaqListed as $MILE! We’re thrilled to have the opportunity to bring fairer and more personalized auto insurance to even more drivers. This is just the beginning of our journey!

Read More


3 biotech trends to watch in 2021

“My sense is that we hit a tipping point this year,” said Mike Pellini, a managing partner at biotech venture capital firm Section 32. “The bottom line is, we can’t treat what we can’t diagnose.”

Read More


Exact Sciences to Acquire Thrive Earlier Detection

Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.

Read More

Pages: 12Last Page